Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma - Wikidata - wikimedia - TriplyDB

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma

http://www.wikidata.org/entity/Q24243100

about

Antibody therapies for lymphoma in children Radiotherapy for advanced-stage aggressive non-Hodgkin lymphoma Antibody therapies for lymphoma in children Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia Anthracycline-containing regimens for treatment of follicular lymphoma in adults Adverse effects of biologics: a network meta-analysis and Cochrane overview Adverse effects of biologics: a network meta-analysis and Cochrane overview Anthracyclines-containing regimens for treatment of follicular lymphoma in adults Bendamustine for patients with B cell lymphoid malignancies Role of rituximab for first-line or relapsed aggressive B-cell lymphoma Myeloablative high-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data I-kappa-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin's lymphoma.Pharmaceutical follow-up for patients on rituximab therapy for non-Hodgkin lymphoma: what is the evidence?Infections in patients taking Rituximab for hematologic malignancies: two-year cohort study.Rituximab in severe skin diseases: target, disease, and dose Initial therapy of mantle cell lymphoma Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.Expanded use of rituximab in the management of non-Hodgkin lymphoma.Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation.Consolidation radiotherapy for advanced-stage aggressive B-cell non-Hodgkin lymphoma: A systematic review and meta-analysis.Rituximab biosimilar evaluated by network meta-analysis.New developments in immunotherapy for lymphoma

P2860

Q24186437-2680E2D6-015A-44ED-AF88-868CA388459C Q24187708-A2F43216-7FB1-4DC3-B023-31670C62081D Q24195106-1E6FF496-5030-4CE1-B75D-AD70C7F68E32 Q24200280-A9A60707-38FC-4F51-9648-B14847DBA0C5 Q24201306-851DD887-736A-42B9-A044-0F01F217762C Q24234197-05F968CB-FC3C-4A5C-839B-6953DAE299B4 Q24235218-065089EF-0DCB-4DFD-A164-70CF52E2A755 Q24236087-CF622C99-9761-453B-AF9D-D972B1958FF0 Q24236426-69BA671D-54C0-44C4-B15C-051227785BA9 Q24236580-7BBF7035-3DA6-4BB0-9FA4-92BCDB053B57 Q24240865-D0C6EF86-B7E3-4C50-B9F7-835CE919F918 Q30500238-08C81597-AD0A-4047-A7A3-BFB3788B7523 Q31036587-17D20B98-4899-4C19-821B-C27A5B42001C Q34133753-33F1D731-958D-4422-8D27-6D87E19F54D6 Q34757945-3D8B7589-202D-48C6-BB39-F5817CB0103B Q34815753-EBAADA01-D4CD-4AF1-887D-6C92737988EB Q35683952-01D299C1-6211-4748-9211-36C0FB52B20F Q36612648-EA4B215D-5B90-4C2D-929B-5C5E7AF559CF Q37391070-500FD356-1F5D-451D-9B34-E7971E7A374A Q37771248-240C5C34-5058-41FA-BF41-C3D1D78C8956 Q37948748-87513AAB-40C1-4D58-B85F-5419F7B6FB2A Q38160456-C791400B-E161-434C-8489-27C5E4631401 Q47139559-0274AC06-5C6C-4E74-BB9F-B968ECA3EB69 Q47151262-F9ACFD2F-8054-4B6C-9552-A47E38985B88 Q58804962-6283C619-18B0-4A25-8085-E6A7B8551465

P2860

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma

http://www.wikidata.org/entity/Q24243100

description

2007 nî lūn-bûn

@nan

2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma

@ast

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma

@en

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma

@en-gb

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma

@nl

type

label

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma

@ast

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma

@en

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma

@en-gb

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma

@nl

prefLabel

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma

@ast

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma

@en

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma

@en-gb

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma

@nl

P1433

Q24243100-197D34C1-83BB-45AB-B96A-44E496B360AC

P1476

Q24243100-5791120B-DC9D-4AA2-A1A5-910E82277758

P2093

Q24243100-539D8D0D-AF6B-42D6-9D0F-115C6B49C27D

Q24243100-9D448DD7-3CB7-4EED-9913-A3A9DB30B35A

Q24243100-A5779D6C-5E34-494D-B145-7AE2DEC2F0C7

Q24243100-C58429F6-6913-41A5-9BAE-D841D5EDDFE8

P2860

Q24243100-13CC05C5-B43D-4E1E-AED9-87C1521D4FCF

Q24243100-173FBFD9-DB3D-48F5-B38D-7BEC268FEA99

Q24243100-1D01772C-FCA1-41E4-BEE3-4A38AB978A8C

Q24243100-29CCECFB-477E-4EC5-85D9-BCD5C6EEE053

Q24243100-3E8EA8C1-7F56-4727-9B79-7A3B82868A86

Q24243100-416FA26E-186D-456E-82B5-70EFB1F0DB91

Q24243100-4620FA73-7366-4226-8271-0F882BCD7524

Q24243100-4F203BC1-A695-4878-A593-4688DE189DF4

Q24243100-51185D91-6171-4208-9032-787954EF1424

Q24243100-66EE85D1-73EE-485F-BFF4-06EC63E1BB48

P31

Q24243100-11d97fd2-3053-4d2c-a488-98ceb38f7fb5

Q24243100-F484D283-23C2-4D2C-BA7B-1554D84BF97B

P356

Q24243100-27F28594-B495-41BF-A6C4-F4AE393B60B7

P50

Q24243100-0C5EEC18-87FE-4BD6-8E2E-B04D38CBB86D

Q24243100-1BE7AC93-5123-4010-B392-A3AFADE785BE

Q24243100-3251FDF6-DC8C-4505-B0A5-31F340BD30BB

Q24243100-38EC4905-E41E-4A84-83B9-92F17C83725A

Q24243100-59836729-D843-4B48-A5F1-0A159EE850B0

Q24243100-AB5FECED-0972-432A-8CCC-A6A87BFA0CFB

Q24243100-C7FBF38B-03FD-496C-824B-F2CD8FA1CFCE

P577

Q24243100-367CC628-A5B9-421E-8679-FFF93FCDAFB3

P698

Q24243100-D49BEAA8-C110-4411-8D2C-02B88EC23F64

P921

Q24243100-3C5D6CC0-DC57-4622-B2B1-1C707F9C1982

P356

14651858.CD003805.PUB2

P1433

Cochrane Database of Systematic Reviews

P1476

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma

@en

P2093

Holger Schulz

http://www.w3.org/2001/XMLSchema#string

Marcel Reiser

http://www.w3.org/2001/XMLSchema#string

Michael Herold

http://www.w3.org/2001/XMLSchema#string

Thilo Kober

http://www.w3.org/2001/XMLSchema#string

P2860

Bias in meta-analysis detected by a simple, graphical test

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

Systematic reviews in health care: Assessing the quality of controlled clinical trials

High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry.

Calculating the number needed to treat for trials where the outcome is time to an event

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.

P31

scholarly article

P356

10.1002/14651858.CD003805.PUB2

http://www.w3.org/2001/XMLSchema#string

P50

Martin Dreyling

Guido Schwarzer

P577

2007-10-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17943799

http://www.w3.org/2001/XMLSchema#string

P921